Highlight: Scientific breakdown of cancer reveals promising results

Sep 09, 2010

The chemical structure of the melanoma-shrinking drug PLX4032 is revealed in a new Nature paper that describes the drug’s discovery, development and functioning.

PLX4032 recently showed promising results in an early clinical trial of patients carrying a mutated version of the BRAF gene. Gideon Bollag and colleagues now explain the science behind the success story.

In particular, they note that sufficiently high levels of the drug, which works by blocking the activity of the oncogenic B-RAF , are needed to yield clinical effects, because the ERK signalling pathway, downstream of B-RAF, needs to be almost completely blocked.

The study demonstrates how the design of early clinical trials based on the biological mechanisms underlying tumour formation can speed the translation of anti-cancer drug from laboratory to clinic. And whilst the long-term effects of PLX4032 remain uncertain, it’s hoped that the small molecule inhibitor prove useful in combination with other targeted agents, immunotherapies or chemotherapies.

Explore further: Exercising restraint to stall tumor growth

More information: Paper: DOI: 10.1038/nature09454

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Better classification to improve treatments for breast cancer

11 hours ago

Breast cancer can be classified into ten different subtypes, and scientists have developed a tool to identify which is which. The research, published in the journal Genome Biology, could improve treatments and targeting of tre ...

Risk of diabetes up in hodgkin's lymphoma survivors

13 hours ago

(HealthDay)—Para-aortic radiation correlates with increased diabetes mellitus (DM) risk for Hodgkin's lymphoma (HL) survivors, according to a study published online Aug. 25 in the Journal of Clinical On ...

User comments : 0